The University of Chicago Header Logo

Connection

Dezheng Huo to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Dezheng Huo has written about Breast Neoplasms.
Dezheng Huo
Connection Strength
18.471
Breast Neoplasms
  1. Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach. Breast Cancer Res. 2024 Oct 29; 26(1):148.
    View in: PubMed
    Score: 0.365
  2. Multi-tissue transcriptome-wide association studies identified 235 genes for intrinsic subtypes of breast cancer. J Natl Cancer Inst. 2024 Jul 01; 116(7):1105-1115.
    View in: PubMed
    Score: 0.357
  3. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities? Cancer Epidemiol Biomarkers Prev. 2024 May 01; 33(5):635-637.
    View in: PubMed
    Score: 0.353
  4. Declination of Treatment, Racial and Ethnic Disparity, and Overall Survival in US Patients With Breast Cancer. JAMA Netw Open. 2024 May 01; 7(5):e249449.
    View in: PubMed
    Score: 0.353
  5. Increase in Hypofractionated Radiation Therapy Among Patients with Invasive Breast Cancer or Ductal Carcinoma In Situ: Who is Left Behind? Pract Radiat Oncol. 2024 Sep-Oct; 14(5):e305-e323.
    View in: PubMed
    Score: 0.352
  6. Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status. Breast Cancer Res. 2024 Mar 21; 26(1):51.
    View in: PubMed
    Score: 0.350
  7. Palliative Care Use Trends, Racial/Ethnic Disparities, and Overall Survival Differences Among Patients With Metastatic Breast Cancer. J Palliat Med. 2024 Jun; 27(6):763-775.
    View in: PubMed
    Score: 0.347
  8. Benign breast disease and breast cancer risk in African women: a case-control study. Cancer Causes Control. 2024 May; 35(5):787-798.
    View in: PubMed
    Score: 0.345
  9. Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2024 Mar; 30(3):651-663.
    View in: PubMed
    Score: 0.337
  10. Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores-Reply. JAMA Oncol. 2023 09 01; 9(9):1299-1300.
    View in: PubMed
    Score: 0.337
  11. A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes. Am J Hum Genet. 2023 06 01; 110(6):950-962.
    View in: PubMed
    Score: 0.329
  12. A metabolome-wide case-control study of african american breast cancer patients. BMC Cancer. 2023 Feb 23; 23(1):183.
    View in: PubMed
    Score: 0.325
  13. The optimization of postoperative radiotherapy in de novo stage IV breast cancer: evidence from real-world data to personalize treatment decisions. Sci Rep. 2023 02 18; 13(1):2880.
    View in: PubMed
    Score: 0.324
  14. Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. Integr Cancer Ther. 2023 Jan-Dec; 22:15347354231185122.
    View in: PubMed
    Score: 0.321
  15. Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017. Int J Radiat Oncol Biol Phys. 2022 03 01; 112(3):654-662.
    View in: PubMed
    Score: 0.295
  16. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
    View in: PubMed
    Score: 0.291
  17. Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nat Commun. 2021 07 07; 12(1):4198.
    View in: PubMed
    Score: 0.290
  18. Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database. Clin Breast Cancer. 2022 01; 22(1):e8-e20.
    View in: PubMed
    Score: 0.288
  19. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients. Breast Cancer Res. 2021 02 04; 23(1):18.
    View in: PubMed
    Score: 0.282
  20. Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. Breast Cancer Res Treat. 2021 Feb; 185(3):841-849.
    View in: PubMed
    Score: 0.276
  21. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. Cancer. 2020 09 01; 126(17):4013-4022.
    View in: PubMed
    Score: 0.269
  22. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
    View in: PubMed
    Score: 0.241
  23. Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. JAMA Oncol. 2018 06 01; 4(6):883-884.
    View in: PubMed
    Score: 0.234
  24. Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev. 2018 06; 27(6):636-643.
    View in: PubMed
    Score: 0.232
  25. Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018 Apr; 168(3):703-712.
    View in: PubMed
    Score: 0.227
  26. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis. 2017 12; 34(8):457-465.
    View in: PubMed
    Score: 0.227
  27. Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiol Biomarkers Prev. 2018 01; 27(1):116-118.
    View in: PubMed
    Score: 0.227
  28. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017 12 01; 3(12):1654-1662.
    View in: PubMed
    Score: 0.226
  29. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018 Feb; 168(1):207-220.
    View in: PubMed
    Score: 0.226
  30. Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer. PLoS Genet. 2017 Sep; 13(9):e1006727.
    View in: PubMed
    Score: 0.223
  31. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. JAMA Oncol. 2017 Jul 01; 3(7):928-935.
    View in: PubMed
    Score: 0.220
  32. Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat. 2017 04; 162(2):317-328.
    View in: PubMed
    Score: 0.213
  33. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016 11 01; 25(21):4835-4846.
    View in: PubMed
    Score: 0.210
  34. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
    View in: PubMed
    Score: 0.208
  35. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016 08 23; 7(34):55231-55248.
    View in: PubMed
    Score: 0.207
  36. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Hum Genet. 2016 10; 135(10):1145-59.
    View in: PubMed
    Score: 0.205
  37. Bayesian adjustment for the misclassification in both dependent and independent variables with application to a breast cancer study. Stat Med. 2016 10 15; 35(23):4252-63.
    View in: PubMed
    Score: 0.204
  38. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. Cancer. 2016 06 15; 122(12):1913-20.
    View in: PubMed
    Score: 0.201
  39. Increased utilization of postmastectomy radiotherapy in the United States from 2003 to 2011 in patients with one to three tumor positive nodes. J Surg Oncol. 2015 Dec; 112(8):809-14.
    View in: PubMed
    Score: 0.195
  40. Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1-T2 and One to Three Positive Lymph Nodes. Ann Surg Oncol. 2015 Dec; 22(13):4295-304.
    View in: PubMed
    Score: 0.188
  41. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015 Apr; 24(2):131-6.
    View in: PubMed
    Score: 0.184
  42. An epidemiologic investigation of physical activity and breast cancer risk in Africa. Cancer Epidemiol Biomarkers Prev. 2014 Dec; 23(12):2748-56.
    View in: PubMed
    Score: 0.181
  43. Utilization of accelerated partial breast irradiation for ductal carcinoma in situ, 2003-2011: report from the national cancer database. Ann Surg Oncol. 2014 Oct; 21(11):3457-65.
    View in: PubMed
    Score: 0.177
  44. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? Oncologist. 2014 Jun; 19(6):592-601.
    View in: PubMed
    Score: 0.176
  45. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. 2013 Dec; 142(3):465-76.
    View in: PubMed
    Score: 0.171
  46. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.168
  47. Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol. 2013 Sep; 23(9):551-7.
    View in: PubMed
    Score: 0.167
  48. Incidence rate of breast cancer in young women. JAMA. 2013 Jun 19; 309(23):2433.
    View in: PubMed
    Score: 0.166
  49. Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis. 2013 Jul; 34(7):1520-8.
    View in: PubMed
    Score: 0.163
  50. A trend analysis of breast cancer incidence rates in the United States from 2000 to 2009 shows a recent increase. Breast Cancer Res Treat. 2013 Apr; 138(2):633-41.
    View in: PubMed
    Score: 0.163
  51. Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis. 2012 Apr; 33(4):835-40.
    View in: PubMed
    Score: 0.151
  52. Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):552-6.
    View in: PubMed
    Score: 0.150
  53. Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Res Treat. 2011 Jun; 127(3):871-7.
    View in: PubMed
    Score: 0.142
  54. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. 2011 Mar 01; 117(5):907-15.
    View in: PubMed
    Score: 0.138
  55. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.127
  56. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol. 2009 Mar 10; 27(8):1184-90.
    View in: PubMed
    Score: 0.123
  57. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15; 14(24):7988-99.
    View in: PubMed
    Score: 0.121
  58. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br J Cancer. 2008 Mar 11; 98(5):992-6.
    View in: PubMed
    Score: 0.115
  59. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
    View in: PubMed
    Score: 0.114
  60. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat. 2008 Jul; 110(2):367-76.
    View in: PubMed
    Score: 0.112
  61. ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.
    View in: PubMed
    Score: 0.091
  62. Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
    View in: PubMed
    Score: 0.090
  63. Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer. Cancer Res. 2024 Aug 01; 84(15):2533-2548.
    View in: PubMed
    Score: 0.090
  64. Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study. Cancer Res Commun. 2024 Jun 27; 4(6):1597-1608.
    View in: PubMed
    Score: 0.089
  65. Racial differences in familiarity, interest, and use of integrative medicine among patients with breast cancer. Breast Cancer Res Treat. 2024 Sep; 207(2):343-359.
    View in: PubMed
    Score: 0.088
  66. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat Genet. 2024 May; 56(5):819-826.
    View in: PubMed
    Score: 0.088
  67. A multi-tissue, splicing-based joint transcriptome-wide association study identifies susceptibility genes for breast cancer. Am J Hum Genet. 2024 06 06; 111(6):1100-1113.
    View in: PubMed
    Score: 0.088
  68. Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.
    View in: PubMed
    Score: 0.088
  69. Novel breast cancer susceptibility loci under linkage peaks identified in African ancestry consortia. Hum Mol Genet. 2024 04 08; 33(8):687-697.
    View in: PubMed
    Score: 0.088
  70. Addition of polygenic risk score to a risk calculator for prediction of breast cancer in US Black women. Breast Cancer Res. 2024 01 02; 26(1):2.
    View in: PubMed
    Score: 0.086
  71. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
    View in: PubMed
    Score: 0.086
  72. Unawareness of breast cancer family history among African women. Pan Afr Med J. 2023; 45:188.
    View in: PubMed
    Score: 0.084
  73. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
    View in: PubMed
    Score: 0.083
  74. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
    View in: PubMed
    Score: 0.082
  75. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.082
  76. Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. JAMA Netw Open. 2023 03 01; 6(3):e233329.
    View in: PubMed
    Score: 0.081
  77. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Med. 2023 01 26; 15(1):7.
    View in: PubMed
    Score: 0.081
  78. Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):98-104.
    View in: PubMed
    Score: 0.080
  79. Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Hum Mol Genet. 2022 09 10; 31(18):3133-3143.
    View in: PubMed
    Score: 0.079
  80. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
    View in: PubMed
    Score: 0.076
  81. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.074
  82. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. J Natl Cancer Inst. 2021 09 04; 113(9):1168-1176.
    View in: PubMed
    Score: 0.073
  83. Development and external validation of a breast cancer absolute risk prediction model in Chinese population. Breast Cancer Res. 2021 05 29; 23(1):62.
    View in: PubMed
    Score: 0.072
  84. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Sci Rep. 2020 06 16; 10(1):9688.
    View in: PubMed
    Score: 0.067
  85. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.067
  86. Prevalence of Inherited Mutations in Breast Cancer Predisposition Genes among Women in Uganda and Cameroon. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):359-367.
    View in: PubMed
    Score: 0.065
  87. Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis. Eur J Epidemiol. 2020 Jun; 35(6):567-578.
    View in: PubMed
    Score: 0.065
  88. Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. Int J Epidemiol. 2019 10 01; 48(5):1727-1730.
    View in: PubMed
    Score: 0.064
  89. Two truncating variants in FANCC and breast cancer risk. Sci Rep. 2019 08 29; 9(1):12524.
    View in: PubMed
    Score: 0.064
  90. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
    View in: PubMed
    Score: 0.064
  91. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. Int J Cancer. 2019 12 15; 145(12):3321-3333.
    View in: PubMed
    Score: 0.063
  92. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.062
  93. The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. Eur J Epidemiol. 2019 Jun; 34(6):591-600.
    View in: PubMed
    Score: 0.061
  94. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Res. 2019 01 14; 21(1):3.
    View in: PubMed
    Score: 0.061
  95. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018 10 16; 9(1):4181.
    View in: PubMed
    Score: 0.060
  96. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clin Cancer Res. 2019 03 15; 25(6):1786-1794.
    View in: PubMed
    Score: 0.059
  97. Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018 10 01; 36(28):2820-2825.
    View in: PubMed
    Score: 0.059
  98. Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Mol Carcinog. 2018 10; 57(10):1311-1318.
    View in: PubMed
    Score: 0.059
  99. Germline Variation and Breast Cancer Incidence: A Gene-Based Association Study and Whole-Genome Prediction of Early-Onset Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2018 09; 27(9):1057-1064.
    View in: PubMed
    Score: 0.059
  100. Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. Int J Cancer. 2018 01 01; 142(1):36-43.
    View in: PubMed
    Score: 0.056
  101. Association of breast cancer risk and the mTOR pathway in women of African ancestry in 'The Root' Consortium. Carcinogenesis. 2017 08 01; 38(8):789-796.
    View in: PubMed
    Score: 0.055
  102. Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction. Breast Cancer Res Treat. 2017 Aug; 164(3):707-717.
    View in: PubMed
    Score: 0.054
  103. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev. 2017 07; 26(7):1016-1026.
    View in: PubMed
    Score: 0.054
  104. Genetic and Epigenetic Regulation of TOX3 Expression in Breast Cancer. PLoS One. 2016; 11(11):e0165559.
    View in: PubMed
    Score: 0.052
  105. miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. Clin Cancer Res. 2017 Feb 15; 23(4):1091-1103.
    View in: PubMed
    Score: 0.051
  106. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 07; 313(13):1347-61.
    View in: PubMed
    Score: 0.047
  107. Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda. Cancer. 2015 Jul 01; 121(13):2237-43.
    View in: PubMed
    Score: 0.047
  108. Alcohol consumption and breast cancer risk among women in three sub-Saharan African countries. PLoS One. 2014; 9(9):e106908.
    View in: PubMed
    Score: 0.045
  109. A comprehensive examination of breast cancer risk loci in African American women. Hum Mol Genet. 2014 Oct 15; 23(20):5518-26.
    View in: PubMed
    Score: 0.044
  110. Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers. Med Phys. 2014 Mar; 41(3):031917.
    View in: PubMed
    Score: 0.044
  111. Use of Web-based training for quality improvement between a field immunohistochemistry laboratory in Nigeria and its United States-based partner institution. Ann Diagn Pathol. 2013 Dec; 17(6):526-30.
    View in: PubMed
    Score: 0.042
  112. Axillary surgery among estrogen receptor positive women 70 years of age or older with clinical stage I breast cancer, 2004-2010: a report from the National Cancer Data Base. Ann Surg Oncol. 2013 Oct; 20(10):3259-65.
    View in: PubMed
    Score: 0.042
  113. Accelerated partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer patients undergoing breast conservation, 2003-2010: a report from the national cancer data base. Ann Surg Oncol. 2013 Oct; 20(10):3223-32.
    View in: PubMed
    Score: 0.042
  114. Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer. 2013 May 10; 12(1):40.
    View in: PubMed
    Score: 0.041
  115. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.041
  116. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393.
    View in: PubMed
    Score: 0.040
  117. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013 Jan; 137(2):373-82.
    View in: PubMed
    Score: 0.040
  118. A genome-wide association study of breast cancer in women of African ancestry. Hum Genet. 2013 Jan; 132(1):39-48.
    View in: PubMed
    Score: 0.039
  119. Protective effect of longstanding lactation and reproductive factors: a case-control study in North Tanzania. Breast Cancer Res Treat. 2012 Aug; 134(3):1349-51.
    View in: PubMed
    Score: 0.039
  120. Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One. 2012; 7(7):e40494.
    View in: PubMed
    Score: 0.039
  121. Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control. 2012 Apr; 23(4):565-74.
    View in: PubMed
    Score: 0.038
  122. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012 Sep 01; 131(5):1114-23.
    View in: PubMed
    Score: 0.038
  123. Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
    View in: PubMed
    Score: 0.038
  124. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012 Jun; 133(3):865-80.
    View in: PubMed
    Score: 0.037
  125. Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer. 2012 Mar 01; 118(5):1362-70.
    View in: PubMed
    Score: 0.037
  126. Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. Int J Cancer. 2012 Jun 01; 130(11):2740-2.
    View in: PubMed
    Score: 0.037
  127. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer. 2011 Jun 13; 11:246.
    View in: PubMed
    Score: 0.036
  128. A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet. 2011 Dec; 130(6):767-75.
    View in: PubMed
    Score: 0.036
  129. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711.
    View in: PubMed
    Score: 0.034
  130. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010 Sep 15; 172(6):682-90.
    View in: PubMed
    Score: 0.034
  131. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010 Dec; 124(3):857-61.
    View in: PubMed
    Score: 0.034
  132. Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet. 2010 Jul 22; 6(7):e1001029.
    View in: PubMed
    Score: 0.034
  133. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.034
  134. Robust segmentation of mass-lesions in contrast-enhanced dynamic breast MR images. J Magn Reson Imaging. 2010 Jul; 32(1):110-9.
    View in: PubMed
    Score: 0.034
  135. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010 Jun; 176(6):2911-20.
    View in: PubMed
    Score: 0.033
  136. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat. 2010 Apr; 120(3):593-601.
    View in: PubMed
    Score: 0.031
  137. Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer. 2009; 8(1):15-22.
    View in: PubMed
    Score: 0.030
  138. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet. 2008 Apr; 123(3):247-55.
    View in: PubMed
    Score: 0.029
  139. Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med. 2007 Jun; 13(5):555-62.
    View in: PubMed
    Score: 0.027
  140. A meta-analysis approach with filtering for identifying gene-level gene-environment interactions. Genet Epidemiol. 2018 07; 42(5):434-446.
    View in: PubMed
    Score: 0.014
  141. Prenatal diethylstilbestrol exposure and cancer risk in women. Environ Mol Mutagen. 2019 06; 60(5):395-403.
    View in: PubMed
    Score: 0.014
  142. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.